GLP-1 medications, commonly used for type 2 diabetes management and weight loss, have garnered attention for their potential benefits in controlling asthma. Recent research suggests that these medications may offer additional advantages, such as reducing obesity-related cancer risk and lowering dementia risk. A study conducted by researchers from the University of Aberdeen and the Observational and Pragmatic Research Institute in the United Kingdom investigated the impact of GLP-1 drugs on asthma control in individuals with obesity.
The findings revealed that individuals taking GLP-1 medications experienced improved asthma control compared to matched controls. These medications, known as GLP-1 receptor agonists, work by mimicking the hormone glucagon-like peptide-1 to regulate blood sugar, increase insulin secretion, reduce gastric emptying, and enhance appetite satiety. By examining a cohort of over 60,000 individuals, including more than 10,000 with both obesity and asthma who were prescribed GLP-1 drugs, the researchers shed light on the potential benefits of these medications for asthma management in individuals with obesity.
Read more from medicalnewstoday.com